Market
Percentage reduction in glucocorticoid doses with Crenessity by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Clinical trial results and medical journals
Story
FDA Approves Neurocrine Biosciences' Crenessity, First New Treatment for CAH in 70 Years
Dec 13, 2024, 08:13 PM
The U.S. Food and Drug Administration (FDA) has approved Neurocrine Biosciences' Crenessity (crinecerfont) for the treatment of adults and pediatric patients over 4 years of age with classic congenital adrenal hyperplasia (CAH). This approval marks the first new treatment option for CAH in 70 years, offering a paradigm-shifting approach by directly reducing excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. The approval was supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH. Crenessity is expected to be commercially available in approximately one week.
View original story
Similar markets
21-30% • 25%
11-20% • 25%
31% or more • 25%
0-10% • 25%
50-69% reduction • 25%
25-49% reduction • 25%
Less than 25% reduction • 25%
70% or more reduction • 25%
Less than 10% • 25%
10% to 20% • 25%
21% to 30% • 25%
More than 30% • 25%
10% to 20% • 25%
More than 30% • 25%
20% to 30% • 25%
Less than 10% • 25%
More than 80% • 25%
Less than 50% • 25%
50% to 74% • 25%
75% to 80% • 25%
22% to 24% weight loss • 25%
More than 24% weight loss • 25%
20% to 22% weight loss • 25%
Less than 20% weight loss • 25%
0-25% reduction • 25%
76-100% reduction • 25%
51-75% reduction • 25%
26-50% reduction • 25%
Heart attack • 25%
Dementia • 25%
Substance abuse • 25%
Schizophrenia • 25%
Rybelsus • 25%
Other • 25%
Ozempic • 25%
Wegovy • 25%
More than 60% • 25%
20% to 40% • 25%
Less than 20% • 25%
40% to 60% • 25%
Wegovy • 25%
Ozempic • 25%
Other • 25%
Janumet • 25%